Subscribe to Newsletter
Business & Regulation Advanced Medicine, Business Practice, COVID-19, Translational Science

Video Roundtable: What can Advanced Medicine Learn from COVID-19?

Developing, approving and manufacturing COVID-19 vaccines – at scale – in a matter of months is a remarkable achievement for the industry – and for society. While COVID-19 was an unprecedented situation, it revealed what may be accomplished under the right circumstances. With this in mind, are there learnings that could be applied to the development and commercialization of advanced therapies? With the field on the cusp of cures for solid tumor cancers, for example, how can we create a sense of urgency around the need to bring these therapies to patients that need them?

Our panel of experts discuss what cell and gene therapy can learn from the pandemic.

Moderator: Jason Foster

CEO, Ori Biotech

Jason is CEO of Ori Biotech, based in London and New Jersey. Ori has developed a fully automated and standardised cell and gene therapy manufacturing platform. And over the past 20 years, Jason has held leading roles building: pharma, consulting and technology companies.


Tamas Masztis

Senior Director, Cell Therapy Supply Chain for Europe at Kite, a Gilead Company

Tamas built one of the first cell therapy supply chains for Europe and Israel. The successful implementation of this complex, centralised end-to-end supply chain involving the transportation of patient cells has been critical to launching Kite's cell therapies in 24 countries in the region to date. Tamas has over 20 years of supply chain, logistics and procurement experience working with blue-chip pharma companies, including Bristol Myers Squibb and Pfizer. In addition to holding a Master's degree in Finance and Marketing from Corvinus University of Budapest, Tamas is also an Institute of Supply Management Certified Purchasing Manager and is Six Sigma Green Belt certified.

Aron F. Stein

Vice President, Global Regulatory Affairs at Sangamo Therapeutics

Aron provides the vision, strategic direction and corporate regulatory approach for all gene and cell therapeutics at Sangamo.  He has over 30 years of product development experience in pharmaceutical and biotechnology having responsibility for multiple drug approvals in both large and small companies. Aron earned his B.S. and PhD at Texas A&M University in toxicology and was a NIEHS postdoctoral fellow at University of Kansas Medical Center. 

Roudie Shafie

Director, OVID Health

Roudie is a Director at OVID Health, a health specialist communication agency, where she leads OVID Health’s cell and gene therapy practice, including the Cell & Gene Collective. She has worked in public policy and campaigning for over 15 years. She is the former Head of Government Affairs at the pharmaceutical trade association and before that led Pfizer UK’s corporate public affairs function. Roudie previously worked for Boris Johnson as Mayor of London where she led policy and strategic projects in health, life sciences and tech. Roudie began her career as an Oxfam campaigner. She is a respected industry thought leader and also serves as a charity trustee.

Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine